Cardiac glycosides use and the risk and mortality of cancer; systematic review and meta-analysis of observational studies
Cardiac glycosides (CGs) including digitalis, digoxin and digitoxin are used in the treatment of congestive heart failure and atrial fibrillation. Pre-clinical studies have investigated the anti-neoplastic properties of CGs since 1960s. Epidemiological studies concerning the association between CGs...
Gespeichert in:
| Veröffentlicht in: | PloS one 2017-06, Vol.12 (6), p.e0178611-e0178611 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e0178611 |
|---|---|
| container_issue | 6 |
| container_start_page | e0178611 |
| container_title | PloS one |
| container_volume | 12 |
| creator | Osman, Mohamed Hosny Farrag, Eman Selim, Mai Osman, Mohamed Samy Hasanine, Arwa Selim, Azza |
| description | Cardiac glycosides (CGs) including digitalis, digoxin and digitoxin are used in the treatment of congestive heart failure and atrial fibrillation. Pre-clinical studies have investigated the anti-neoplastic properties of CGs since 1960s. Epidemiological studies concerning the association between CGs use and cancer risk yielded inconsistent results. We have performed a systematic review and meta-analysis to summarize the effects of CGs on cancer risk and mortality.
PubMed, Scopus, Cochrane library, Medline and Web of Knowledge were searched for identifying relevant studies. Summary relative risks (RR) and 95% confidence intervals (CI) were calculated using random-effects model.
We included 14 case-control studies and 15 cohort studies published between 1976 and 2016 including 13 cancer types. Twenty-four studies reported the association between CGs and cancer risk and six reported the association between CGs and mortality of cancer patients. Using CGs was associated with a higher risk of breast cancer (RR = 1.330, 95% CI: 1.247-1.419). Subgroup analysis showed that using CGs increased the risk of ER+ve breast cancer but not ER-ve. Using CGs wasn't associated with prostate cancer risk (RR = 1.015, 95% CI: 0.868-1.87). However, CGs decreased the risk in long term users and showed a protective role in decreasing the risk of advanced stages. CGs use was associated with increased all-cause mortality (HR = 1.35, 95% CI: 1.248-1.46) but not cancer-specific mortality (HR = 1.075, 95% CI: 0.968-1.194).
The anti-tumor activity of CGs observed in pre-clinical studies requires high concentrations which can't be normally tolerated in humans. However, the estrogen-like activity of CGs could be responsible for increasing the risk of certain types of tumors. |
| doi_str_mv | 10.1371/journal.pone.0178611 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_1907228574</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A494688613</galeid><doaj_id>oai_doaj_org_article_c1f5f983c71d4b4c92ac600fcc36c9c5</doaj_id><sourcerecordid>A494688613</sourcerecordid><originalsourceid>FETCH-LOGICAL-c692t-65f9a37cef838f61638c6bd7edd89454f910784727b01f7a13673a8bbbc2cb663</originalsourceid><addsrcrecordid>eNqNk1uL1DAUx4so7rr6DUQLgujDjEnTJi2CsAxeBhYWvL2GND2dydg2sznpar-96U53mco-SB6anv7O_1x6ThQ9p2RJmaDvdrZ3nWqWe9vBklCRc0ofRKe0YMmCJ4Q9PLqfRE8Qd4RkLOf8cXSS5FlBaUZPo2GlXGWUjjfNoC2aCjDuEWLVVbHfQuwM_rp5aa3zqjF-iG0da9VpcO9jHNBDq7zRsYNrA78PKHi1UCG3AQ2OuC0R3HXAbDDG6PvKAD6NHtWqQXg2Pc-iH58-fl99WVxcfl6vzi8WmheJX_CsLhQTGuqc5TWnnOWal5WAqsqLNEvrghKRpyIRJaG1UJRxwVRelqVOdMk5O4teHnT3jUU5dQ0lLYhIQh9EGoj1gais2sm9M61yg7TKyBuDdRupXKixAalpHfLJmRa0SstUF4nSnJBaa8Z1obOg9WGK1pctVBo671QzE51_6cxWbuy1zFKesGJM980k4OxVD-hla1BD06gObH_ImyUsYySgr_5B769uojYqFGC62oa4ehSV52mR8jwMDgvU8h4qnApao8OI1SbYZw5vZw6B8fDHb1SPKNffvv4_e_lzzr4-YregGr9F2_Tj8OAcTA-gdhbRQX3XZErkuCG33ZDjhshpQ4Lbi-MfdOd0uxLsL1emDSE</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1907228574</pqid></control><display><type>article</type><title>Cardiac glycosides use and the risk and mortality of cancer; systematic review and meta-analysis of observational studies</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Public Library of Science (PLoS) Journals Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Osman, Mohamed Hosny ; Farrag, Eman ; Selim, Mai ; Osman, Mohamed Samy ; Hasanine, Arwa ; Selim, Azza</creator><contributor>Quintas, Luis Eduardo M.</contributor><creatorcontrib>Osman, Mohamed Hosny ; Farrag, Eman ; Selim, Mai ; Osman, Mohamed Samy ; Hasanine, Arwa ; Selim, Azza ; Quintas, Luis Eduardo M.</creatorcontrib><description>Cardiac glycosides (CGs) including digitalis, digoxin and digitoxin are used in the treatment of congestive heart failure and atrial fibrillation. Pre-clinical studies have investigated the anti-neoplastic properties of CGs since 1960s. Epidemiological studies concerning the association between CGs use and cancer risk yielded inconsistent results. We have performed a systematic review and meta-analysis to summarize the effects of CGs on cancer risk and mortality.
PubMed, Scopus, Cochrane library, Medline and Web of Knowledge were searched for identifying relevant studies. Summary relative risks (RR) and 95% confidence intervals (CI) were calculated using random-effects model.
We included 14 case-control studies and 15 cohort studies published between 1976 and 2016 including 13 cancer types. Twenty-four studies reported the association between CGs and cancer risk and six reported the association between CGs and mortality of cancer patients. Using CGs was associated with a higher risk of breast cancer (RR = 1.330, 95% CI: 1.247-1.419). Subgroup analysis showed that using CGs increased the risk of ER+ve breast cancer but not ER-ve. Using CGs wasn't associated with prostate cancer risk (RR = 1.015, 95% CI: 0.868-1.87). However, CGs decreased the risk in long term users and showed a protective role in decreasing the risk of advanced stages. CGs use was associated with increased all-cause mortality (HR = 1.35, 95% CI: 1.248-1.46) but not cancer-specific mortality (HR = 1.075, 95% CI: 0.968-1.194).
The anti-tumor activity of CGs observed in pre-clinical studies requires high concentrations which can't be normally tolerated in humans. However, the estrogen-like activity of CGs could be responsible for increasing the risk of certain types of tumors.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0178611</identifier><identifier>PMID: 28591151</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Anticancer properties ; Antitumor agents ; Biology and Life Sciences ; Breast cancer ; Cancer ; Cardiac glycosides ; Cardiac Glycosides - adverse effects ; Colorectal cancer ; Confidence intervals ; Congestive heart failure ; Digitalis ; Digoxin ; Epidemiology ; Estrogen receptors ; Estrogens ; Female ; Fibrillation ; Glycosides ; Health aspects ; Health risk assessment ; Health risks ; Heart ; Hormone replacement therapy ; Human papillomavirus ; Humans ; Libraries ; Male ; Mathematical models ; Medical diagnosis ; Medicine and Health Sciences ; Meta-analysis ; Mortality ; Neoplasms - mortality ; Observational studies ; Observational Studies as Topic ; Ovarian cancer ; Patients ; Physical Sciences ; Prostate cancer ; Research and Analysis Methods ; Risk assessment ; Risk Factors ; Studies ; Tumors ; Xenografts</subject><ispartof>PloS one, 2017-06, Vol.12 (6), p.e0178611-e0178611</ispartof><rights>COPYRIGHT 2017 Public Library of Science</rights><rights>2017 Osman et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2017 Osman et al 2017 Osman et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c692t-65f9a37cef838f61638c6bd7edd89454f910784727b01f7a13673a8bbbc2cb663</citedby><cites>FETCH-LOGICAL-c692t-65f9a37cef838f61638c6bd7edd89454f910784727b01f7a13673a8bbbc2cb663</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5462396/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5462396/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,728,781,785,865,886,2103,2929,23871,27929,27930,53796,53798</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28591151$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Quintas, Luis Eduardo M.</contributor><creatorcontrib>Osman, Mohamed Hosny</creatorcontrib><creatorcontrib>Farrag, Eman</creatorcontrib><creatorcontrib>Selim, Mai</creatorcontrib><creatorcontrib>Osman, Mohamed Samy</creatorcontrib><creatorcontrib>Hasanine, Arwa</creatorcontrib><creatorcontrib>Selim, Azza</creatorcontrib><title>Cardiac glycosides use and the risk and mortality of cancer; systematic review and meta-analysis of observational studies</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Cardiac glycosides (CGs) including digitalis, digoxin and digitoxin are used in the treatment of congestive heart failure and atrial fibrillation. Pre-clinical studies have investigated the anti-neoplastic properties of CGs since 1960s. Epidemiological studies concerning the association between CGs use and cancer risk yielded inconsistent results. We have performed a systematic review and meta-analysis to summarize the effects of CGs on cancer risk and mortality.
PubMed, Scopus, Cochrane library, Medline and Web of Knowledge were searched for identifying relevant studies. Summary relative risks (RR) and 95% confidence intervals (CI) were calculated using random-effects model.
We included 14 case-control studies and 15 cohort studies published between 1976 and 2016 including 13 cancer types. Twenty-four studies reported the association between CGs and cancer risk and six reported the association between CGs and mortality of cancer patients. Using CGs was associated with a higher risk of breast cancer (RR = 1.330, 95% CI: 1.247-1.419). Subgroup analysis showed that using CGs increased the risk of ER+ve breast cancer but not ER-ve. Using CGs wasn't associated with prostate cancer risk (RR = 1.015, 95% CI: 0.868-1.87). However, CGs decreased the risk in long term users and showed a protective role in decreasing the risk of advanced stages. CGs use was associated with increased all-cause mortality (HR = 1.35, 95% CI: 1.248-1.46) but not cancer-specific mortality (HR = 1.075, 95% CI: 0.968-1.194).
The anti-tumor activity of CGs observed in pre-clinical studies requires high concentrations which can't be normally tolerated in humans. However, the estrogen-like activity of CGs could be responsible for increasing the risk of certain types of tumors.</description><subject>Anticancer properties</subject><subject>Antitumor agents</subject><subject>Biology and Life Sciences</subject><subject>Breast cancer</subject><subject>Cancer</subject><subject>Cardiac glycosides</subject><subject>Cardiac Glycosides - adverse effects</subject><subject>Colorectal cancer</subject><subject>Confidence intervals</subject><subject>Congestive heart failure</subject><subject>Digitalis</subject><subject>Digoxin</subject><subject>Epidemiology</subject><subject>Estrogen receptors</subject><subject>Estrogens</subject><subject>Female</subject><subject>Fibrillation</subject><subject>Glycosides</subject><subject>Health aspects</subject><subject>Health risk assessment</subject><subject>Health risks</subject><subject>Heart</subject><subject>Hormone replacement therapy</subject><subject>Human papillomavirus</subject><subject>Humans</subject><subject>Libraries</subject><subject>Male</subject><subject>Mathematical models</subject><subject>Medical diagnosis</subject><subject>Medicine and Health Sciences</subject><subject>Meta-analysis</subject><subject>Mortality</subject><subject>Neoplasms - mortality</subject><subject>Observational studies</subject><subject>Observational Studies as Topic</subject><subject>Ovarian cancer</subject><subject>Patients</subject><subject>Physical Sciences</subject><subject>Prostate cancer</subject><subject>Research and Analysis Methods</subject><subject>Risk assessment</subject><subject>Risk Factors</subject><subject>Studies</subject><subject>Tumors</subject><subject>Xenografts</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>DOA</sourceid><recordid>eNqNk1uL1DAUx4so7rr6DUQLgujDjEnTJi2CsAxeBhYWvL2GND2dydg2sznpar-96U53mco-SB6anv7O_1x6ThQ9p2RJmaDvdrZ3nWqWe9vBklCRc0ofRKe0YMmCJ4Q9PLqfRE8Qd4RkLOf8cXSS5FlBaUZPo2GlXGWUjjfNoC2aCjDuEWLVVbHfQuwM_rp5aa3zqjF-iG0da9VpcO9jHNBDq7zRsYNrA78PKHi1UCG3AQ2OuC0R3HXAbDDG6PvKAD6NHtWqQXg2Pc-iH58-fl99WVxcfl6vzi8WmheJX_CsLhQTGuqc5TWnnOWal5WAqsqLNEvrghKRpyIRJaG1UJRxwVRelqVOdMk5O4teHnT3jUU5dQ0lLYhIQh9EGoj1gais2sm9M61yg7TKyBuDdRupXKixAalpHfLJmRa0SstUF4nSnJBaa8Z1obOg9WGK1pctVBo671QzE51_6cxWbuy1zFKesGJM980k4OxVD-hla1BD06gObH_ImyUsYySgr_5B769uojYqFGC62oa4ehSV52mR8jwMDgvU8h4qnApao8OI1SbYZw5vZw6B8fDHb1SPKNffvv4_e_lzzr4-YregGr9F2_Tj8OAcTA-gdhbRQX3XZErkuCG33ZDjhshpQ4Lbi-MfdOd0uxLsL1emDSE</recordid><startdate>20170607</startdate><enddate>20170607</enddate><creator>Osman, Mohamed Hosny</creator><creator>Farrag, Eman</creator><creator>Selim, Mai</creator><creator>Osman, Mohamed Samy</creator><creator>Hasanine, Arwa</creator><creator>Selim, Azza</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20170607</creationdate><title>Cardiac glycosides use and the risk and mortality of cancer; systematic review and meta-analysis of observational studies</title><author>Osman, Mohamed Hosny ; Farrag, Eman ; Selim, Mai ; Osman, Mohamed Samy ; Hasanine, Arwa ; Selim, Azza</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c692t-65f9a37cef838f61638c6bd7edd89454f910784727b01f7a13673a8bbbc2cb663</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Anticancer properties</topic><topic>Antitumor agents</topic><topic>Biology and Life Sciences</topic><topic>Breast cancer</topic><topic>Cancer</topic><topic>Cardiac glycosides</topic><topic>Cardiac Glycosides - adverse effects</topic><topic>Colorectal cancer</topic><topic>Confidence intervals</topic><topic>Congestive heart failure</topic><topic>Digitalis</topic><topic>Digoxin</topic><topic>Epidemiology</topic><topic>Estrogen receptors</topic><topic>Estrogens</topic><topic>Female</topic><topic>Fibrillation</topic><topic>Glycosides</topic><topic>Health aspects</topic><topic>Health risk assessment</topic><topic>Health risks</topic><topic>Heart</topic><topic>Hormone replacement therapy</topic><topic>Human papillomavirus</topic><topic>Humans</topic><topic>Libraries</topic><topic>Male</topic><topic>Mathematical models</topic><topic>Medical diagnosis</topic><topic>Medicine and Health Sciences</topic><topic>Meta-analysis</topic><topic>Mortality</topic><topic>Neoplasms - mortality</topic><topic>Observational studies</topic><topic>Observational Studies as Topic</topic><topic>Ovarian cancer</topic><topic>Patients</topic><topic>Physical Sciences</topic><topic>Prostate cancer</topic><topic>Research and Analysis Methods</topic><topic>Risk assessment</topic><topic>Risk Factors</topic><topic>Studies</topic><topic>Tumors</topic><topic>Xenografts</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Osman, Mohamed Hosny</creatorcontrib><creatorcontrib>Farrag, Eman</creatorcontrib><creatorcontrib>Selim, Mai</creatorcontrib><creatorcontrib>Osman, Mohamed Samy</creatorcontrib><creatorcontrib>Hasanine, Arwa</creatorcontrib><creatorcontrib>Selim, Azza</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection (ProQuest)</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Osman, Mohamed Hosny</au><au>Farrag, Eman</au><au>Selim, Mai</au><au>Osman, Mohamed Samy</au><au>Hasanine, Arwa</au><au>Selim, Azza</au><au>Quintas, Luis Eduardo M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cardiac glycosides use and the risk and mortality of cancer; systematic review and meta-analysis of observational studies</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2017-06-07</date><risdate>2017</risdate><volume>12</volume><issue>6</issue><spage>e0178611</spage><epage>e0178611</epage><pages>e0178611-e0178611</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Cardiac glycosides (CGs) including digitalis, digoxin and digitoxin are used in the treatment of congestive heart failure and atrial fibrillation. Pre-clinical studies have investigated the anti-neoplastic properties of CGs since 1960s. Epidemiological studies concerning the association between CGs use and cancer risk yielded inconsistent results. We have performed a systematic review and meta-analysis to summarize the effects of CGs on cancer risk and mortality.
PubMed, Scopus, Cochrane library, Medline and Web of Knowledge were searched for identifying relevant studies. Summary relative risks (RR) and 95% confidence intervals (CI) were calculated using random-effects model.
We included 14 case-control studies and 15 cohort studies published between 1976 and 2016 including 13 cancer types. Twenty-four studies reported the association between CGs and cancer risk and six reported the association between CGs and mortality of cancer patients. Using CGs was associated with a higher risk of breast cancer (RR = 1.330, 95% CI: 1.247-1.419). Subgroup analysis showed that using CGs increased the risk of ER+ve breast cancer but not ER-ve. Using CGs wasn't associated with prostate cancer risk (RR = 1.015, 95% CI: 0.868-1.87). However, CGs decreased the risk in long term users and showed a protective role in decreasing the risk of advanced stages. CGs use was associated with increased all-cause mortality (HR = 1.35, 95% CI: 1.248-1.46) but not cancer-specific mortality (HR = 1.075, 95% CI: 0.968-1.194).
The anti-tumor activity of CGs observed in pre-clinical studies requires high concentrations which can't be normally tolerated in humans. However, the estrogen-like activity of CGs could be responsible for increasing the risk of certain types of tumors.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>28591151</pmid><doi>10.1371/journal.pone.0178611</doi><tpages>e0178611</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2017-06, Vol.12 (6), p.e0178611-e0178611 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_1907228574 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Public Library of Science (PLoS) Journals Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central; Free Full-Text Journals in Chemistry |
| subjects | Anticancer properties Antitumor agents Biology and Life Sciences Breast cancer Cancer Cardiac glycosides Cardiac Glycosides - adverse effects Colorectal cancer Confidence intervals Congestive heart failure Digitalis Digoxin Epidemiology Estrogen receptors Estrogens Female Fibrillation Glycosides Health aspects Health risk assessment Health risks Heart Hormone replacement therapy Human papillomavirus Humans Libraries Male Mathematical models Medical diagnosis Medicine and Health Sciences Meta-analysis Mortality Neoplasms - mortality Observational studies Observational Studies as Topic Ovarian cancer Patients Physical Sciences Prostate cancer Research and Analysis Methods Risk assessment Risk Factors Studies Tumors Xenografts |
| title | Cardiac glycosides use and the risk and mortality of cancer; systematic review and meta-analysis of observational studies |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-13T14%3A00%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cardiac%20glycosides%20use%20and%20the%20risk%20and%20mortality%20of%20cancer;%20systematic%20review%20and%20meta-analysis%20of%20observational%20studies&rft.jtitle=PloS%20one&rft.au=Osman,%20Mohamed%20Hosny&rft.date=2017-06-07&rft.volume=12&rft.issue=6&rft.spage=e0178611&rft.epage=e0178611&rft.pages=e0178611-e0178611&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0178611&rft_dat=%3Cgale_plos_%3EA494688613%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1907228574&rft_id=info:pmid/28591151&rft_galeid=A494688613&rft_doaj_id=oai_doaj_org_article_c1f5f983c71d4b4c92ac600fcc36c9c5&rfr_iscdi=true |